This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dyax Corp. Announces Five HAE Allies℠ Honorees, Underscoring Critical Role Of Support For Patients With Hereditary Angioedema

Dyax Corp. (NASDAQ: DYAX) today announced five HAE Allies honorees chosen as the first to be recognized by the program for their contributions in supporting those with hereditary angioedema (HAE) to live life to the fullest. By drawing from the inspiring stories of individuals nationwide, the HAE Allies program hopes to underscore the value of support for those living with this potentially life-threatening condition, which is characterized by spontaneous episodes of edema, or swelling, in the face, feet, hands, throat and abdomen.

The honorees were selected by a multi-disciplinary council of HAE experts organized by Dyax, the developer and marketer of KALBITOR® (ecallantide) for the treatment of sudden attacks of HAE in patients 16 years of age and older. Ranging from health care providers to loved ones to community members working to educate the public about HAE, the 2013 honorees are:
  • Douglas Jones, MD of Salt Lake City, Utah
  • Barbara Mathews, RN of Frisco, Texas
  • Justin Wright of Washington, Utah
  • Ernie Seawright of Decatur, Georgia
  • Chief Donald Sayre (retired) of Tarpon Springs, Florida

“The program received an impressive group of nominations, each of which illustrated how one person can truly make a difference in the life of another,” said Donna Davis, Assistant Vice President for Patient Services and Clinical Programs of the Hereditary Angioedema Association (HAEA) and HAE Allies council member.

At the launch of the program in May 2013, HAE patients across the country were asked to nominate people in their lives who provide the support which enables them to better manage their condition, to achieve their personal and professional goals, or cope with the unpredictability of HAE. The selection of the honorees coincided with the HAEA’s National Patient Summit, held in Orlando, Florida in September. In addition to a donation to the HAEA for every nomination submitted, grants will be made by Dyax in each honoree’s name to the HAE advocacy organization of their choice.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,683.58 -46.53 -0.26%
S&P 500 2,068.76 -8.02 -0.39%
NASDAQ 4,991.94 -17.2740 -0.34%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs